Jacobs Levy Equity Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Jacobs Levy Equity Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$165M	Sell	214,160 -50,831	-19%	-$38.9M	0.7%	28
2025 Q4	$205M	Sell	264,991 -22,890	-8%	-$15.5M	0.79%	26
2025 Q3	$162M	Buy	287,881 +53,614	+23%	+$30.3M	0.64%	35
2025 Q2	$123M	Buy	234,267 +233,520	+31,261%	+$130M	0.48%	50
2025 Q1	$474K	Sell	747 -100	-12%	-$68.8K	﹤0.01%	923
2024 Q4	$603K	Sell	847 -22,744	-96%	-$19.1M	﹤0.01%	790
2024 Q3	$24.8M	Buy	23,591 +10,213	+76%	+$11.4M	0.1%	200
2024 Q2	$14.1M	Buy	13,378 +13,016	+3,596%	+$12.6M	0.06%	284
2024 Q1	$348K	Buy	362 +6	+2%	+$5.71K	﹤0.01%	847
2023 Q4	$313K	Buy	+356	New	+$293K	﹤0.01%	884
2022 Q1	–	Sell	-350	Closed	-$221K	–	1074
2021 Q4	$221K	Buy	+350	New	+$215K	﹤0.01%	930
2018 Q2	–	Sell	-1,178	Closed	-$406K	–	1084
2018 Q1	$406K	Buy	+1,178	New	+$410K	0.01%	810
2016 Q3	–	Sell	-30,328	Closed	-$10.6M	–	1106
2016 Q2	$10.6M	Buy	30,328 +29,753	+5,174%	+$11.5M	0.22%	140
2016 Q1	$207K	Buy	+575	New	+$237K	﹤0.01%	963

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Jacobs Levy Equity Management's REGN Position: Q1 2026 in Review

Jacobs Levy Equity Management reduced its Regeneron Pharmaceuticals (REGN) stake by 19% in Q1 2026, selling an estimated $38.9M and leaving 214,160 shares worth $165M. The position accounts for 0.7% of the portfolio, ranked #28.

Jacobs Levy Equity Management first reported a position in REGN in Q1 2016 and has held it in 14 quarters since. The position peaked at $205M in Q4 2025. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Jacobs Levy Equity Management held 214,160 shares of Regeneron Pharmaceuticals worth $165M as of Q1 2026.
Jacobs Levy Equity Management sold 50,831 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $38.9M.
Regeneron Pharmaceuticals made up 0.7% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #28 holding.
Jacobs Levy Equity Management first reported a position in Regeneron Pharmaceuticals in Q1 2016 and has held it in 14 quarters since.
Jacobs Levy Equity Management's Regeneron Pharmaceuticals position peaked at $205M in Q4 2025.
1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.